Table III.
A, Disease-free survival | ||
---|---|---|
Parameter | HR (95% CI) | P-value |
Tumor size, cm (≤6 vs. >6 cm) | 2.670 (1.704–4.183) | <0.001 |
Tumor number (single vs. multiple) | 1.092 (0.692–1.723) | 0.707 |
Metastasis (no vs. yes) | 1.116 (0.685–1.816) | 0.660 |
BCLC stage (0-A vs. B-C) | 1.835 (1.116–3.018) | 0.017 |
RECQL4 mRNA (low vs. high) | 1.635 (1.062–2.515) | 0.025 |
B, Overall survival | ||
Parameter | HR (95% CI) | P-value |
Tumor size, cm (≤6 vs. >6 cm) | 2.536 (1.621–3.967) | <0.001 |
Tumor number (single vs. multiple) | 1.033 (0.652–1.637) | 0.890 |
Metastasis (no vs. yes) | 1.212 (0.742–1.981) | 0.443 |
BCLC stage (0-A vs. B-C) | 1.679 (1.021–2.760) | 0.041 |
Recurrence (no vs. yes) | 2.832 (1.827–4.391) | <0.001 |
RECQL4 mRNA (low vs. high) | 1.618 (1.050–2.493) | 0.029 |
HR, hazard ratio; CI, confidence interval; metastasis, distant metastasis or lymph node metastasis; BCLC, Barcelona Clinic Liver Cancer; RECQL4, ATP-dependent DNA helicase Q4.